SCHEDULE: Streeterville Capital Discloses 9.3% Stake in Vivos Therapeutics

Streeterville Capital LLC, along with affiliated entities, has reported beneficial ownership of 1,812,031 shares, representing 9.3% of Vivos Therapeutics, Inc. common stock.

Summary

• Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife have jointly filed a Schedule 13G.
• They collectively beneficially own 1,812,031 shares of Vivos Therapeutics, Inc. common stock.
• This ownership stake represents 9.3% of the total outstanding shares.
• The filing is based on 19,570,972 shares outstanding as of August 10, 2026.
• Streeterville Capital LLC holds the shares directly, with the other entities having indirect beneficial ownership.
• The reporting persons certify that the shares were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake taken by an investment firm. The lack of commentary on strategic intent or future plans tempers a more enthusiastic assessment.

Positives

• Significant ownership stake of 9.3% by Streeterville Capital LLC and its affiliates, indicating substantial investor interest.
• Clear disclosure of beneficial ownership, providing transparency to the market.
• The reporting persons certify that the shares are not held for the purpose of influencing control, which can be seen as a positive signal of passive investment.

Negatives

• The filing is a Schedule 13G, which is typically for passive investors, suggesting no immediate intent to influence management or strategy.
• Lack of detailed commentary on the rationale behind the investment or future intentions.

Risks

• Potential for increased market volatility if Streeterville Capital decides to alter its investment strategy or dispose of shares.
• The concentration of ownership could be a factor in future corporate actions, though the filing suggests no intent to influence control.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance or strategy.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology and healthcare sectors, often indicating strategic investment by specialized funds. Vivos Therapeutics operates in the medical device space, specifically focusing on obstructive sleep apnea.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant shareholder's position. May influence market perception and trading activity.
• Management: Awareness of a substantial passive investor, which could be a factor in future strategic decisions, though direct influence is disclaimed.
• Creditors: Indirect impact through potential changes in company stability or strategic direction, though the passive nature of the investment limits immediate concern.

Next Steps

• Continued monitoring of Vivos Therapeutics' performance and any subsequent filings by Streeterville Capital LLC or other significant shareholders.
• Potential for Streeterville Capital to increase or decrease its stake in the future, which would trigger new filings.

Key Dates

Recommendation

The filing indicates a significant passive investment by Streeterville Capital, which is a common occurrence for institutional investors. However, without further information on the company's performance, strategic direction, or the investor's specific intentions beyond passive ownership, a 'hold' recommendation is prudent. The 9.3% stake is notable but does not inherently signal a need to buy or sell based solely on this disclosure.

Keywords

Vivos Therapeutics, Streeterville Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Shareholder